|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:Thomas_Schinecker
|
|
gptkbp:chairman
|
gptkb:Christoph_Franz
|
|
gptkbp:country
|
gptkb:Switzerland
|
|
gptkbp:division
|
Diagnostics Division
Pharmaceuticals Division
|
|
gptkbp:founded
|
1896
|
|
gptkbp:founder
|
gptkb:Fritz_Hoffmann-La_Roche
|
|
gptkbp:headquarters_location
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Roche Holding AG
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:ISIN
|
CH0012032048
|
|
gptkbp:legalForm
|
Aktiengesellschaft (AG)
|
|
gptkbp:listedOn
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:logo
|
Roche logo.svg
|
|
gptkbp:marketCap
|
over CHF 200 billion (2023)
|
|
gptkbp:member
|
gptkb:International_Federation_of_Pharmaceutical_Manufacturers_&_Associations
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:netIncome
|
CHF 13.5 billion (2023)
|
|
gptkbp:notableAcquisition
|
gptkb:Foundation_Medicine_(2018)
gptkb:Genentech_(2009)
Flatiron Health (2018)
Spark Therapeutics (2019)
|
|
gptkbp:notableContributor
|
immunology
infectious diseases
neuroscience
oncology
ophthalmology
|
|
gptkbp:numberOfEmployees
|
over 100,000
|
|
gptkbp:product
|
gptkb:Evrysdi
gptkb:Phesgo
gptkb:Ronapreve
gptkb:Venclexta
gptkb:Actemra
gptkb:Alecensa
gptkb:Avastin
gptkb:Esbriet
gptkb:Gazyva
gptkb:Hemlibra
gptkb:Herceptin
gptkb:Kadcyla
gptkb:MabThera
gptkb:Ocrevus
gptkb:Perjeta
gptkb:Polivy
gptkb:Rituxan
gptkb:Rozlytrek
gptkb:Tamiflu
gptkb:Tecentriq
gptkb:Xeloda
|
|
gptkbp:revenue
|
CHF 63.3 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:ROG
|
|
gptkbp:subsidiary
|
gptkb:Genentech
gptkb:Foundation_Medicine
gptkb:Chugai_Pharmaceutical
|
|
gptkbp:website
|
https://www.roche.com
|
|
gptkbp:主要株主
|
gptkb:Roche_family
Novartis (historically, until 2021)
|
|
gptkbp:bfsParent
|
gptkb:Museum_Tinguely
gptkb:Roche_family
|
|
gptkbp:bfsLayer
|
6
|